PDF(Pubmed)
Abstract：
UNASSIGNED: Chronic liver disease (CLD) is a complex disease associated with profound dysfunction. Despite an incredible burden, the first and only pharmacotherapy for metabolic-associated steatohepatitis was only approved in March of this year, indicating a gap in the translation of preclinical studies. There is a body of preclinical work on the application of phosphodiesterase 4 inhibitors in CLD, none of these molecules have been successfully translated into clinical use.
UNASSIGNED: To design therapies to combat CLD, it is essential to consider the dysregulation of other tissues that contribute to its development and progression. As such, proper therapies must combat this throughout the body rather than focusing only on the liver. To detail this, literature characterizing the pathogenesis of CLD was pulled from PubMed, with a particular focus placed on the role of PDE4 in inflammation and metabolism. Then, the focus is shifted to detailing the available information on existing PDE4 inhibitors.
UNASSIGNED: This review gives a brief overview of some of the pathologies of organ systems that are distinct from the liver but contribute to disease progression. The demonstrated efficacy of PDE4 inhibitors in other human inflammatory diseases should earn them further examination for the treatment of CLD.
UNASSIGNED: To design therapies to combat CLD, it is essential to consider the dysregulation of other tissues that contribute to its development and progression. As such, proper therapies must combat this throughout the body rather than focusing only on the liver. To detail this, literature characterizing the pathogenesis of CLD was pulled from PubMed, with a particular focus placed on the role of PDE4 in inflammation and metabolism. Then, the focus is shifted to detailing the available information on existing PDE4 inhibitors.
UNASSIGNED: This review gives a brief overview of some of the pathologies of organ systems that are distinct from the liver but contribute to disease progression. The demonstrated efficacy of PDE4 inhibitors in other human inflammatory diseases should earn them further examination for the treatment of CLD.
摘要：
■慢性肝病（CLD）是一种与严重功能障碍相关的复杂疾病。尽管有令人难以置信的负担，第一个也是唯一一个代谢相关脂肪性肝炎的药物疗法仅在今年3月获得批准，表明临床前研究的翻译存在差距。关于磷酸二酯酶4抑制剂在CLD中的应用，有大量的临床前工作。这些分子均未成功转化为临床应用。
■为了设计对抗CLD的疗法，必须考虑其他组织的失调，这有助于其发展和进展。因此，适当的治疗必须在整个身体中对抗这种情况，而不是只关注肝脏。要详细说明这一点，描述CLD发病机理的文献来自PubMed，特别关注PDE4在炎症和代谢中的作用。然后，重点转移到详述现有PDE4抑制剂的可用信息。
■这篇综述简要概述了一些与肝脏不同但有助于疾病进展的器官系统病理。PDE4抑制剂在其他人类炎性疾病中的已证实的功效应该使他们进一步检查CLD的治疗。
■为了设计对抗CLD的疗法，必须考虑其他组织的失调，这有助于其发展和进展。因此，适当的治疗必须在整个身体中对抗这种情况，而不是只关注肝脏。要详细说明这一点，描述CLD发病机理的文献来自PubMed，特别关注PDE4在炎症和代谢中的作用。然后，重点转移到详述现有PDE4抑制剂的可用信息。
■这篇综述简要概述了一些与肝脏不同但有助于疾病进展的器官系统病理。PDE4抑制剂在其他人类炎性疾病中的已证实的功效应该使他们进一步检查CLD的治疗。
